Results 21 to 30 of about 2,343,081 (240)

Mineralocorticoid Receptor Antagonists [PDF]

International Cardiovascular Forum Journal, 2019
Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
  +5 more sources

The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice

Pharmaceutics, 2023
Tacrolimus (Tac) is a calcineurin inhibitor commonly used as an immunosuppressor after solid organ transplantation. However, Tac may induce hypertension, nephrotoxicity, and an increase in aldosterone levels.
Stefanny M. Figueroa, Jean-Philippe Bertocchio, Toshifumi Nakamura, Soumaya El-Moghrabi, Frédéric Jaisser, Cristián A. Amador   +5 more
doaj   +1 more source

Cell-specific mineralocorticoid receptors: future therapeutic targets for stroke?

Neural Regeneration Research, 2016
Quynh N Dinh, Grant R Drummond, Christopher G Sobey, Sophocles Chrissobolis   +3 more
doaj   +2 more sources

Cardiorenal benefits of finerenone: protecting kidney and heart

Annals of Medicine, 2023
Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors.
José R. González-Juanatey, Jose Luis Górriz, Alberto Ortiz, Alfonso Valle, Maria Jose Soler, Lorenzo Facila   +5 more
doaj   +1 more source

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor mutations [PDF]

Journal of Endocrinology, 2017
Aldosterone and the mineralocorticoid receptor (MR) are key elements for maintaining fluid and electrolyte homeostasis as well as regulation of blood pressure. Loss-of-function mutations of the MR are responsible for renal pseudohypoaldosteronism type 1 (PHA1), a rare disease of mineralocorticoid resistance presenting in the newborn with weight loss ...
Maria-Christina, Zennaro, Fabio, Fernandes-Rosa   +1 more
openaire   +2 more sources

New Perspectives on Sex Steroid and Mineralocorticoid Receptor Signaling in Cardiac Ischemic Injury

Frontiers in Physiology, 2022
The global burden of ischemic heart disease is burgeoning for both men and women. Although advances have been made, the need for new sex-specific therapies targeting key differences in cardiovascular disease outcomes in men and women remains ...
Laura A. Bienvenu, Laura A. Bienvenu, James R. Bell, Kate L. Weeks, Kate L. Weeks, Lea M. D. Delbridge, Morag J. Young, Morag J. Young   +7 more
doaj   +1 more source

Pseudohypoaldosteronism Type 1 with a Novel Mutation in the Gene: A Case Report [PDF]

Childhood Kidney Diseases, 2020
Pseudohypoaldosteronism type 1 (PHA1) is a rare salt-wasting disorder caused by resistance to mineralocorticoid action. PHA1 is of two types with different levels of disease severity and phenotype as follows: systemic type with an autosomal recessive ...
Young Min Kim, In Su Choi, Hae Il Cheong, Chan Jong Kim, Eun Mi Yang   +4 more
doaj   +1 more source

Distinct regulation of hippocampal neuroplasticity and ciliary genes by corticosteroid receptors

Nature Communications, 2021
Glucocorticoid hormones (GCs) are of critical importance for maintaining brain health, but their involvement in mental disorders is poorly understood. Here the authors show how GCs act through hippocampal mineralocorticoid and glucocorticoid receptors to
Karen R. Mifsud, Clare L. M. Kennedy, Silvia Salatino, Eshita Sharma, Emily M. Price, Samantha N. Haque, Andriana Gialeli, Hannah M. Goss, Polina E. Panchenko, John Broxholme, Simon Engledow, Helen Lockstone, Oscar Cordero Llana, Johannes M. H. M. Reul   +13 more
doaj   +1 more source

Nuclear receptors in vascular biology [PDF]

, 2015
Nuclear receptors sense a wide range of steroids and hormones (estrogens, progesterone, androgens, glucocorticoid, and mineralocorticoid), vitamins (A and D), lipid metabolites, carbohydrates, and xenobiotics.
A Chawla, A McCurley, AA Hamers, AL Bookout, B Fisslthaler, BG Hoebel, C McCarthy, C Zhou, CH Lee, CK Glass, CK Huang, CT Lee, D Bishop-Bailey, D Bishop-Bailey, David Bishop-Bailey, DP Edwards, E Gerlach, F Akbiyik, FA Pereira, FL Wynne, FY Ali, G Pascual, I Dussault, I Spoletini, J He, J Qin, J Sonoda, J Xiang, K Spruiell, KE Swales, L Calza, L Li, L Piqueras, LA Moraes, LA Moraes, LJ Jonk, LR You, M Kaushik, M Matic, N Albermann, N Schafer, N Takamoto, Q Qin, R Zhao, S Asgary, S Chakrabarti, S Marino De, S Stein, SA Kliewer, V Zoete, W El-Sankary, WC Lau, X Wang, Y Ma, Y Sui, Y Sui, YW Hu   +56 more
core   +3 more sources

Drug treatment of hypertension: focus on vascular health [PDF]

, 2016
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C., Lang, Ninian N., Touyz, Rhian M.   +2 more
core   +1 more source